BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HRS8807 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HRS8807\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04993430-9177@assetmemo.bio
DTSTAMP:20261121T005452Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:HRS8807: Phase 1 readout est. (NCT04993430)
DESCRIPTION:HRS8807\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStudy:
  A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in
  Subjects With ER-Positive\, HER2-Negative Metastatic or Locally Advanced 
 Breast Cancer\nEstimated primary completion: 30 December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/hrs8807#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04993430
URL:https://assetmemo.bio/drug/hrs8807#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
